Erleada

To the best of my knowledge ERLEADA is a hormone reduction treatment similar to Lupron and others. How it will impact you is always the great unknown.
When I was on Lupron ( oh what a joy) I had significant issues with mood swings (crying for no reason) a 27lb weight gain, night sweats and ongoing hot flashes.
At the same time there were guys in our support group who said they did not experience any negative impacts.
A neighbor just recently told me his 6 month Lupron had no impact on him other than slight issues with loss of sex drive and some minor issues with intercourse - I had to laugh because while I was on Lupron I had ZERO interest and ZERO ability to "rise to the occasion". My reaction to the 6 month shot lasted 14 months. The trouble is your reactions if any will depend on how the drug hits your system.
Best advice is to deep breadth and keep your MD informed - Give it a chance but at the same time do not suffer endlessly if you are having some real issues. There are some things you can take to help you over a difficult period.
Also good to remind your MD that he has most likely not taken the drug. While it is easy for him to say just live with it - YOU are living with it and it can be very challenging --- do not put up with that" just man up" attitude. Ask questions and be direct. .... Dennis(ProstateCancer.net Team)

Thank you Dennis.I just started on it and I feel good so far.The cost for a one month prescription was over 12,000 dollars.Thank God I have coverage.I don’t know how long I will be on it.

Hi Yardboy1. Glad you are handling the treatment well so far. I just wanted to share with you this article from Urology Today on a study which found "Treatment with ERLEADA (apalutamide) plus androgen deprivation therapy (ADT) resulted in a 25 percent reduction in the risk of death compared with placebo plus ADT in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases:" https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-prostate-cancer/115201-updated-results-of-the-spartan-study-show-25-percent-reduction-in-the-risk-of-death-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-treated-with-erleada-apalutamide.html. Hoping you see great results. Best, Richard (ProstateCancer.net Team)